Old and new: Appropriate dosing for neonatal antifungal drugs in the nursery

Early Human Development

Volumn 89, Issue SUPPL.1, 2013, Pages

  Ericson, Jessica ^a   Manzoni, Paolo ^b   Benjamin, Daniel K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Candida; Dosing; Echinocandin; Fluconazole; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; HIGH RISK INFANT; HUMAN; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; PREMATURITY; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ECHINOCANDINS; FLUCONAZOLE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INTENSIVE CARE UNITS, NEONATAL; NEONATOLOGY; PYRIMIDINES; TRIAZOLES;

EID: 84879817702     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/S0378-3782(13)70009-4     Document Type: Review

References (16)

1. Benjamin DK, Poole C, Steinbach WJ, Rowen JL, Walsh TJ Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003, 112(3 Pt 1):634-640.
2. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
3. Rowen JL, Tate JM, Neonatal Candidiasis Study Group Management of neonatal candidiasis. Pediatr Infect Dis J 1998, 17(11):1007-1011.
4. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009, 28(12):1061-1063.
5. Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J 2012, 31(5):439-443.
6. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005, 49(12):5092-5098.
7. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55(10):1352-1361.
8. Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011, 30(5):375-378.
9. Doby EH, Benjamin DK, Blaschke AJ, Ward RM, Pavia AT, Martin PL, et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J 2012, 31(6):632-635.
10. Driscoll TA, Frangoul H, Nemecek ER, Murphey DK, Yu LC, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother 2011, 55(12):5780-5789.
11. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010, 50(1):27-36.
12. Etienne KA, Subudhi CP, Chadwick PR, Settle P, Moise J, Magill SS, et al. Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit. J Hosp Infect 2011, 79(4):344-348.
13. Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008, 197(1):163-171.
14. Ascher S, Smith PB, Benjamin DK Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf 2011, 10(2):281-286.
15. Saez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009, 53(3):869-875.
16. Cohen-Wolkowiez M, Benjamin DK, Piper L, Cheifetz IM, Moran C, Liu P, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011, 89(5):702-707.